Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 288 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: docosahexaenoic acid OR corn/soy oil placebo Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid

NCT02719327
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
icosapent ethyl (IPE), gel cap placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 11, 2026, 8:45 AM EDT
Not listed Phase 2Phase 3 Interventional

The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity

NCT02260973
View directory record Official record
Conditions
Cataract, Dry Eye Disease
Interventions
Omega-3 (Triglyceride form)
Dietary Supplement
Lead sponsor
Physician Recommended Nutriceuticals
Industry
Eligibility
30 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Lexington, Kentucky • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Oct 11, 2026, 8:45 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Docosahexaenoic Acid (DHA) Supplementation in High Risk Pregnancies

NCT04069195
View directory record Official record
Conditions
Inflammation, Pregnancy Related
Interventions
DHA supplement, Corn Oil: Soybean Oil
Dietary Supplement
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 11, 2026, 8:45 AM EDT
Recruiting Not applicable Interventional

Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

NCT05380401
View directory record Official record
Conditions
Premature
Interventions
Enfamil® DHA & ARA Supplement for Special Dietary Use
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Up to 36 Weeks
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 11, 2026, 8:45 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Oral Nutrition Impact on Tear Film

NCT01561040
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega 3, Vitamins A, D3 and E
Dietary Supplement
Lead sponsor
Eye and Vision Technologies and Research Institute
Network
Eligibility
18 Years to 79 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
4
States / cities
Conifer, Colorado • Oak Lawn, Illinois • Lexington, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Oct 11, 2026, 8:45 AM EDT
Withdrawn Phase 4 Interventional

A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid

NCT04811404
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Ethyl Eicosapentaenoic Acid
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

NCT01178892
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Placebo, Omega-3, Yoga, Exercise, Usual Activity
Dietary Supplement · Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Oakland, California • Indianapolis, Indiana • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 22, 2014 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Phase 4 Interventional Results available

Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial

NCT00795717
View directory record Official record
Conditions
Cardiovascular Disease, HIV Infection
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Tufts University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 11, 2026, 8:45 AM EDT
Terminated Phase 2 Interventional Results available

OPTIMA-TBI Pilot Study

NCT03345550
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Omega-3 Polyunsaturated Fatty Acids (Fish Oil 1000 mg (contains 500 mg DHA & 100 mg EPA)) or placebo capsules., Placebo - Cap
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Evaluation of Cow Milk-Based Formulas

NCT00518414
View directory record Official record
Conditions
Term Infants
Interventions
Marketed infant formula with DHA and ARA, Milk-based infant formula with DHA and ARA, Milk-based formula with DHA, ARA, prebiotics
Other
Lead sponsor
Mead Johnson Nutrition
Industry
Eligibility
10 Days to 18 Days
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Tamarac, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Oct 11, 2026, 8:45 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

NCT01803711
View directory record Official record
Conditions
Major Depression, Cancer, Diabetes, Cardiovascular Diseases
Interventions
Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement)
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

NCT01047501
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
80
States / cities
Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study

NCT01285362
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Fish Oil Supplementation, Placebo Supplementation
Drug
Lead sponsor
Columbia University
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)

NCT01747447
View directory record Official record
Conditions
Bone Density, Body Composition, Bone Health
Interventions
Vitamin D3 placebo, Fish oil placebo, omega-3 fatty acids (fish oil), Vitamin D3
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
771 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Memory Improvement With Docosahexaenoic Acid Study (MIDAS)

NCT00278135
View directory record Official record
Conditions
Age-Related Cognitive Decline, Age-Related Memory Disorders
Interventions
DHA (nutritional supplement) or placebo
Dietary Supplement
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
55 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
14
States / cities
Mesa, Arizona • San Diego, California • Vista, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prenatal DHA and Neurofunctional Development

NCT02709239
View directory record Official record
Conditions
Use and Dose of Prenatal DHA Supplementation
Interventions
DHA 200mg, DHA 800mg
Dietary Supplement
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Docosahexaenoic Acid in the Treatment of Autism

NCT00577447
View directory record Official record
Conditions
Autism
Interventions
docosahexaenoic acid (DHA), Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 10 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional Results available

Effect of EPA and HMB on Strength in ICU Patients

NCT01270516
View directory record Official record
Conditions
Muscle Weakness
Interventions
HMB, hydroxymethylbutyrate, EPA, eicosapentaenoic acid, Saline
Drug
Lead sponsor
Gerald Supinski
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome

NCT00344721
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Omega-3 fatty acid supplement, Placebo
Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of DHA on Periodontitis

NCT01976806
View directory record Official record
Conditions
Periodontitis, Gingivitis, Inflammation
Interventions
Aspirin, Docosahexaenoic acid, Placebo (for Docosahexaenoic acid)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Omega-3 Long Chain Polyunsaturated Fatty Acid (LCPUFA) Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity

NCT02486042
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Omegaven, Standard lipids (primarily omega-6 fatty acids)
Drug · Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 7 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Oct 11, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

NCT01154400
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Casein protein hydrolysates, Whey protein hydrolysates, Casein protein hydrolysates + LEU, Whey protein hydrolysates + LEU
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 11, 2026, 8:45 AM EDT